Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Passes Above 200 Day Moving Average – Here’s Why

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $46.19 and traded as high as $50.43. Global X Genomics & Biotechnology ETF shares last traded at $48.56, with a volume of 6,369 shares trading hands.

Global X Genomics & Biotechnology ETF Stock Down 4.2%

The business has a 50-day simple moving average of $45.94 and a two-hundred day simple moving average of $46.19. The stock has a market capitalization of $54.39 million, a P/E ratio of -20.75 and a beta of 1.21.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of large investors have recently bought and sold shares of GNOM. IFP Advisors Inc grew its position in Global X Genomics & Biotechnology ETF by 20.8% in the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares during the period. Smartleaf Asset Management LLC boosted its stake in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares in the last quarter. Sei Investments Co. boosted its stake in Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after purchasing an additional 12,105 shares in the last quarter. Wealth Management Partners LLC acquired a new position in Global X Genomics & Biotechnology ETF in the first quarter worth $244,000. Finally, Creative Financial Designs Inc. ADV boosted its stake in Global X Genomics & Biotechnology ETF by 4.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after purchasing an additional 481 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.